Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

180 Life Sciences Corp (ATNF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow 180 Life Sciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.950 -0.010    -0.51%
19:12:35 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 8,759
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.880 - 2.000
Type:  Equity
Market:  United States
180 Life Sciences 1.950 -0.010 -0.51%

180 Life Sciences Company Profile

 
Read the 180 Life Sciences Corp company profile to learn more about the business and the management team. View 180 Life Sciences Corp facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

4

Equity Type

ORD

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.

Contact Information

Address Building 4 Suite 200
3000 El Camino Real Palo Alto, 94306
United States
Phone 650 507 0669
Fax -

Top Executives

Name Age Since Title
Jagdeep Nanchahal - - Co-Founder & Chairman of Clinical Advisory Board
Blair Jordan - 2024 Lead Independent Director
Lawrence Steinman 76 2019 Co-Founder & Executive Chairman
Sallie Lamb - 2022 Member of Scientific Advisory Board
James N. Woody 82 2020 CEO & Director
Kevin J. Tracey - 2022 Member of Scientific Advisory Board
Irene Tracey - 2022 Member of Scientific Advisory Board
Chas Bountra - 2022 Member of Scientific Advisory Board
Omar J. Jimenez 62 2024 Independent Director
Ryan L. Smith 41 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATNF Price Commentary

Write your thoughts about 180 Life Sciences Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
mr low
mr low Apr 13, 2021 10:58
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy the dips and hold, setting sell to $100+ & remove loss limits then watch the shorts burn!
Hodl Handz
Hodl Handz Mar 26, 2021 14:37
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Come on go to 20 plzzzzzz
Lee Strongitharm
Lee Strongitharm Feb 05, 2021 12:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is going to the moon!
Charalambos Charalambous
Charalambos Charalambous Feb 05, 2021 12:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why can you explain to me pls
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email